Switching From Originator Biological Agents to Biosimilars: What Is the Evidence and What Are the Issues?

RMD Open - United Kingdom
doi 10.1136/rmdopen-2017-000492
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy